Ignite Creation Date:
2025-12-25 @ 12:39 AM
Ignite Modification Date:
2026-01-25 @ 12:59 AM
Study NCT ID:
NCT02508467
Status:
COMPLETED
Last Update Posted:
2024-04-12
First Post:
2015-07-09
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma
Sponsor:
Blueprint Medicines Corporation
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Hepatocellular Carcinoma (HCC) | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Liver cancer | View |
| None | FGF19 gene amplification | View |
| None | FGF19 overexpression | View |
| None | FGF19 upregulation | View |
| None | Cyclin D1 (CCND1) gene amplification | View |
| None | Cyclin D1 (CCND1) copy number gain | View |
| None | BLU-554 | View |
| None | FGFR4 | View |
| None | Hepatocellular carcinoma | View |
| None | Liver Disease | View |
| None | Liver Neoplasms | View |